GlassScriptPhysician profile
William K Walsh
NPI 1982602785
$14,407.43
in general payments reported to CMS, 2019-2025
67 companies · $3,224 in 2025
The $3,224 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $445 · 2021: $126 · 2022: $2,488 · 2023: $3,025 · 2024: $2,914 · 2025: $3,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,162.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,309.28 | 2019-2025 | |
| Pfizer INC. | $979.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $960.15 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $851.22 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $822.52 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Gilead Sciences, INC. | $609.14 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $601.49 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $568.23 | 2019-2025 | Phesgo, Venclexta, Perjeta |
| Eisai INC. | $561.07 | 2022-2025 | |
| Seagen INC. | $493.85 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Amgen INC. | $441.79 | 2019-2023 | Kyprolis, Blincyto |
| Incyte Corporation | $421.63 | 2019-2025 | Monjuvi, Pemazyre, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $407.39 | 2019-2025 | Ninlaro |
| Abbvie INC. | $391.90 | 2019-2025 | Venclexta |
| Celgene Corporation | $381.49 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $373.45 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $361.05 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $352.86 | 2019-2025 | |
| Daiichi Sankyo INC. | $347.46 | 2020-2025 | Injectafer, Enhertu |
| Puma Biotechnology, INC. | $277.37 | 2019-2025 | |
| Exelixis INC. | $276.23 | 2022-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $256.78 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Bayer Healthcare Pharmaceuticals INC. | $187.19 | 2019-2024 | |
| Taiho Oncology, INC. | $164.39 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $145.53 | 2022-2025 | |
| Emd Serono, INC. | $124.73 | 2019-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $110.46 | 2019-2024 | Ultomiris |
| Astellas Pharma US INC | $91.95 | 2019-2025 | Vyloy |
| Tersera Therapeutics LLC | $85.24 | 2023-2025 | Xermelo, Zoladex |
| Morphosys, US INC. | $78.25 | 2021-2023 | Monjuvi |
| Beigene USA, INC. | $77.93 | 2023-2025 | Brukinsa |
| Cti Biopharma Corp. | $77.27 | 2022-2023 | Vonjo |
| Tempus Ai, INC | $68.36 | 2025 | Xt Cdx |
| Legend Biotech USA INC. | $60.17 | 2025 | Carvykti |
| Array Biopharma INC | $58.53 | 2025 | Braftovi, Mektovi, Lorbrena |
| Sun Pharmaceutical Industries INC. | $55.06 | 2025 | |
| Springworks Therapeutics, INC. | $53.24 | 2025 | Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.77 | 2019-2025 | |
| Kite Pharma, INC. | $52.13 | 2023-2025 | Yescarta |
| Sobi, INC | $49.14 | 2023-2025 | |
| Verastem, INC. | $47.98 | 2019-2020 | |
| Clovis Oncology, INC. | $45.19 | 2019 | |
| Genmab U.S., INC. | $45.14 | 2023-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $43.20 | 2024-2025 | |
| Mirati Therapeutics, INC. | $42.96 | 2023-2024 | Krazati |
| Recordati_rare_diseases_inc. | $42.59 | 2025 | Enjaymo, Sylvant |
| Stemline Therapeutics INC. | $40.70 | 2023-2024 | Orserdu |
| Secura Bio, INC. | $36.69 | 2019-2022 | |
| Coherus Oncology, INC. | $36.26 | 2024 | |
| Blueprint Medicines Corporation | $34.27 | 2022-2023 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $30.40 | 2022-2024 | Cosela |
| Sumitomo Pharma America, INC. | $29.08 | 2023 | Orgovyx |
| Adc Therapeutics America, INC. | $28.71 | 2022-2024 | |
| Beone Medicines USA, INC. | $26.01 | 2025 | Brukinsa |
| Azurity Pharmaceuticals, INC. | $25.00 | 2025 | Danziten |
| Aveo Pharmaceuticals, INC. | $24.55 | 2025 | |
| Geron Corporation | $24.07 | 2025 | Rytelo |
| Syndax Pharmaceuticals, INC. | $23.23 | 2025 | |
| Adaptive Biotechnologies Corporation | $19.53 | 2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $18.51 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $16.59 | 2023 | Libtayo |
| Celltrion USA INC. | $16.21 | 2025 | Vegzelma |
| Teva Pharmaceuticals USA, INC. | $15.98 | 2019 | |
| Mylan Institutional INC. | $15.76 | 2019 | |
| Corcept Therapeutics | $14.39 | 2025 | Korlym |
| Aimmune Therapeutics, INC. | $14.01 | 2025 | Zenpep |
| Iovance Biotherapeutics, INC. | $11.75 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.